Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Rhea-AI Summary
Profound Medical (NASDAQ:PROF) congratulated Texas Prostate and Dr. James Cochran for completing their 100th TULSA Procedure at Dallas Medical Center on March 27, 2026. Texas Prostate reported a 500% increase in TULSA volumes after shifting from private-pay to a Medicare collaboration, expanding patient access.
The TULSA Procedure uses the TULSA-PRO system with MRI-guided, robotic directional ultrasound and real-time thermography to ablate prostate tissue with precise temperature control.
Positive
- 100th TULSA Procedure milestone achieved by Texas Prostate
- Procedure volumes rose by 500% after Medicare collaboration
- MRI-guided real-time thermography enables precise, autonomous temperature control
- No overnight hospital stay and minimal procedural blood loss reported
Negative
- None.
News Market Reaction – PROF
On the day this news was published, PROF declined 1.75%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PROF gained 8.25% while key peers were mostly down: OWLT -2.19%, RCEL -2.28%, LNSR -0.54%, RPID -4.6%, with only SERA up 1.53%, pointing to stock-specific strength tied to this TULSA utilization milestone.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Clinical trial data | Positive | -0.7% | CAPTAIN trial showed better safety outcomes for TULSA vs robotic prostatectomy. |
| Mar 09 | Conference preview | Neutral | -1.5% | Announcement of CAPTAIN data presentation and investor events schedule. |
| Mar 05 | Earnings results | Neutral | -29.1% | Reported record Q4 and 2025 revenue, larger net loss, financing and growth plans. |
| Feb 12 | Earnings date set | Neutral | +5.9% | Scheduled Q4 and full-year results release and follow-up conference call. |
| Feb 12 | Award & adoption | Positive | -3.3% | Mount Logan Award and milestones such as the 4,000th TULSA patient treated. |
Recent history shows several positive operational and clinical updates (e.g., CAPTAIN trial success, awards, revenue growth) followed by muted or negative next-day moves, indicating a pattern where strong news has not consistently produced sustained upside.
Over the last few months, Profound reported multiple milestones, including CAPTAIN trial safety success on Mar 13, 2026, investor event announcements, and record Q4-2025 revenue of $6.0M with full-year $16.1M. It also received the Mount Logan Award recognizing the TULSA Procedure and highlighted CMS reimbursement and global expansion. Despite generally constructive news, price reactions ranged from -29.11% on earnings to modest gains and declines, suggesting that prior positive developments did not always translate into immediate upside as today’s utilization milestone did.
Regulatory & Risk Context
The company has an inactive Form S-3 shelf filed on 2025-11-13 to register up to $150,000,000 of securities, including common shares, warrants, debt, subscription receipts and units, for working capital, capital expenditures and general corporate purposes, with specific terms to be set in future prospectus supplements.
Market Pulse Summary
This announcement highlights continued real‑world uptake of the TULSA Procedure, with Texas Prostate reaching 100 completed treatments and reporting a 500% volume increase after shifting to a Medicare-based model. It reinforces TULSA’s positioning as an MRI‑guided, incision‑free option for prostate disease. In context of prior CAPTAIN trial data, revenue growth, and an existing $150,000,000 shelf, investors may focus on how procedure volumes, reimbursement dynamics, and future financing choices evolve over time.
Key Terms
hifu medical
thermography medical
benign prostatic hyperplasia medical
bph medical
robotically controlled directional ultrasound medical
mri thermography medical
AI-generated analysis. Not financial advice.
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, is pleased to announce that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure™ performed in Dallas Medical Center’s state-of-the-art MRI suite.
“Having performed hundreds of focal HIFU procedures for prostate cancer patients, we switched to primarily offering the TULSA Procedure because its unique MRI-guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities, and aggressions, with an improved safety profile. With TULSA, by planning and delivering therapy under continuous, in‑bore MRI visualization — rather than relying on diagnostic images obtained weeks or months earlier and aligned indirectly at the time of treatment in the case of HIFU — we gain a clearer, more accurate understanding of tumor location and extent, enabling more precise and safer therapy,” said Dr. Cochran. “Almost immediately upon transitioning from a private pay to a Medicare model via our new collaboration with Dallas Medical Center, our TULSA Procedure numbers increased by
“Under this innovative model pioneered by Texas Prostate — bridging private-pay practices and Medicare-participating hospitals — Dr. Cochran is demonstrating a way for urologists to accelerate adoption of the next generation of prostate care by allowing more men to benefit from the TULSA Procedure’s versatility across the full spectrum of prostate disease,” commented Arun Menawat, Profound’s CEO and Chairman. “On behalf of everyone at Profound, we would like to congratulate Dr. Cochran and his team on his first 100 TULSA Procedures.”
The TULSA Procedure, performed using the TULSA-PRO® system, represents a major advancement in prostate care, and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (“BPH”, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to ‘kill temperature’ (55-57°C), while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay, and a quicker return to everyday life, while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.
The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care — from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the safety and efficacy of Profound’s technology in the treatment of prostate cancer, BPH, pain palliation of bone metastases, desmoid tumors, osteoid osteoma, uterine fibroids and adenomyosis. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.com and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195
